Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Treatment with KU758 is associated with overall statistically significant upregulation of long noncoding RNA expression, including the tumor suppressor GAS5, which is implicated in the β-catenin and mammalian target of rapamycin pathways in adrenocortical carcinoma.
|
31561992 |
2020 |
Adrenocortical carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Comprehensive analysis of CTNNB1 in adrenocortical carcinomas: Identification of novel mutations and correlation to survival.
|
29872083 |
2018 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This study aimed to explore the effect of MED27 on the expression of epithelial-mesenchymal transition (EMT)-related proteins and β-catenin in adrenal cortical carcinoma (ACC).
|
29730647 |
2018 |
Adrenocortical carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation.
|
29532999 |
2018 |
Adrenocortical carcinoma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma.
|
28114280 |
2017 |
Adrenocortical carcinoma
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Adrenocortical carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We sequenced PRKACA, GNAS and CTNNB1 genes in 108 patients, including 60 patients with CPAs (57 with unilateral and three with bilateral adenomas), 13 with nonfunctional adenomas, 12 with adrenocortical carcinomas (ACCs), 15 with primary bilateral macronodular hyperplasia (PBMAH) and eight with aldosterone and cortisol cosecreting adenomas.
|
27296931 |
2016 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The pathogenesis of the adrenocortical cancer (ACC) involves integration of molecular signals and the interplay of different downstream pathways (i.e.IGFII/IGF1R, β-catenin, Wnt, ESR1).
|
26312764 |
2015 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Loss of β-catenin in adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-mesenchymal transition.
|
25823656 |
2015 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
CTD_human |
Integrated genomic characterization of adrenocortical carcinoma.
|
24747642 |
2014 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Silencing mutated β-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R.
|
23409032 |
2013 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Low SGK1 protein levels, but not nuclear β-catenin and phosphorylated AKT, were associated with poor overall survival in patients with adrenocortical carcinoma (P < 0.005; hazard ratio = 2.0; 95% confidence interval = 1.24-3.24), independent of tumor stage and GC secretion.
|
23055545 |
2012 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Previous studies have identified overexpression of insulin-like growth factor 2 (IGF-2) and constitutive activation of β-catenin as key factors involved in the development of adrenocortical carcinoma.
|
21386792 |
2011 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Additionally, the characterization of Wnt signaling through β-catenin in adrenal development, the demonstration of the involvement of BMP signaling in adrenocortical carcinoma growth regulation, and the discovery that ERCC1 expression levels can predict therapeutic response to platinum are just a few of the recent advances that promise to shed light on adrenocortical carcinoma biology.
|
21045685 |
2011 |
Adrenocortical carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations of β-catenin gene (CTNNB1) are frequent in adrenocortical adenomas (AA) and adrenocortical carcinomas (ACC).
|
21565795 |
2011 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
β-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma.
|
21088256 |
2011 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
ACTs from patients with FAP and sporadic adrenocortical carcinomas (ACC) with abnormal β-catenin localization on immunohistochemistry but no somatic β-catenin mutations were studied.
|
20978149 |
2010 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
A role of beta-catenin (CTNNB1) in the molecular pathogenesis of adrenocortical carcinoma (ACC) has been suspected in adult ACC and pediatric pigmented nodular adrenocortical disease, but it has never been reported in pediatric ACC.
|
19863445 |
2010 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells.
|
18544621 |
2008 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In adrenocortical adenomas, beta-catenin alterations are more frequent in nonfunctioning tumors, suggesting that beta-catenin pathway activation might be mostly involved in the development of nonsecreting adrenocortical adenomas and adrenocortical carcinomas.
|
16140927 |
2005 |